1-8 of 8
Simon P. Joel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

GCS-100 Targets Apoptosis and Cell Cycle Regulation in Myeloma Cells.

Matthew Streetly, BMBS, MRCP, MRCPath, Lenushka Maharaj, Simon P Joel, Finbarr E Cotter, FRCP, FRCPath, PhD
Journal: Blood
Blood (2009) 114 (22): 4923.
https://doi.org/10.1182/blood.V114.22.4923.4923
Published: 2009
Journal Articles

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Simone Juliger, Takayuki Nakashima, Lenushka Maharaj, Toshihiko Ishii, Hiroshi Nakagawa, Yutaka Kanda, Heather Oakervee, James Cavenagh, Shiro Akinaga, Yukimasa Shiotsu, Simon P Joel
Journal: Blood
Blood (2008) 112 (11): 1625.
https://doi.org/10.1182/blood.V112.11.1625.1625
Published: 2008
Journal Articles

The Novel HDAC Inhibitor UCL67022 Is Highly Potent in Multiple Myeloma and Non-Hodgkin’s Lymphoma and Is Enhanced by Bortezomib.

Lenushka Maharaj, Rakesh Popat, Angela Chahwan, Andrew T. Lister, James D. Cavenagh, Brian Middleton, Alf Rioja, Charles Marson, Simon P. Joel
Journal: Blood
Blood (2006) 108 (11): 2604.
https://doi.org/10.1182/blood.V108.11.2604.2604
Published: 2006
Journal Articles

The Activity of the Novel Aurora Kinase B Inhibitor AZD1152 in Acute Myeloid Leukaemia Cells.

Simon P. Joel, PhD, Adedayo Oke, PhD, Nichola Foot, BSc, Nick Keen, PhD, Dominique Bonnet, PhD, Thomas A. Lister, MD, Jude Fitzgibbon, PhD
Journal: Blood
Blood (2005) 106 (11): 3374.
https://doi.org/10.1182/blood.V106.11.3374.3374
Published: 2005
Journal Articles

Changes in Mcl-1 and Bim Expression with Bortezomib and Melphalan Therapy for Multiple Myeloma.

Rakesh Popat, DipRCPath, Lyndsey Goff, PhD, Heather E. Oaekervee, MRCPath, Jamie D. Cavenagh, MD, Simon P. Joel, PhD
Journal: Blood
Blood (2005) 106 (11): 2481.
https://doi.org/10.1182/blood.V106.11.2481.2481
Published: 2005
Journal Articles

Methylseleninic Acid Results in Rapid Changes in Intracellular Selenium Species and Sensitises Human Lymphoma Cells to Doxorubicin.

Simone Juliger, PhD, Heidi Goenaga-Infante, PhD, Jude Fitzgibbon, PhD, Andrew T. Lister, MD, Simon P. Joel, PhD
Journal: Blood
Blood (2005) 106 (11): 1768.
https://doi.org/10.1182/blood.V106.11.1768.1768
Published: 2005
Journal Articles

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Sandra J. Strauss, MD, Lenushka Maharaj, MSc, Jim Stec, Anthony Boral, MD, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Simon P. Joel, PhD, T. Andrew Lister, MD
Journal: Blood
Blood (2004) 104 (11): 1386.
https://doi.org/10.1182/blood.V104.11.1386.1386
Published: 2004
Journal Articles

Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System.

Lenushka Maharaj, MSc, Sandra J. Strauss, MD, Jim Stec, Thomas A. Lister, Simon P. Joel, PhD
Journal: Blood
Blood (2004) 104 (11): 3294.
https://doi.org/10.1182/blood.V104.11.3294.3294
Published: 2004